Literature DB >> 12848753

Optimizing antibiotic therapy-the Aberdeen experience.

Y Kumarasamy1, T Cadwgan, I A Gillanders, B Jappy, R Laing, I M Gould.   

Abstract

OBJECTIVE: To study the quality and continuity of treatment in the Acute Medicines Assessment Unit (AMAU) with regard to empirical prescription of antibiotics, mode of administration, adherence to ward antibiotic policy, as well as collection, awareness and utilization of microbiological investigations.
METHODS: A prospective study over a 3-month period at the AMAU, Aberdeen Royal Infirmary (ARI), a teaching hospital in north-eastern Scotland, was performed. The study included all patients started on empirical antibiotics on admission to the AMAU and followed up until their discharge.
RESULTS: Of 1303 patients admitted, 221 (17%) were started on empirical antibiotics. This was in accordance with hospital antibiotic policy in 52% of cases. Appropriate specimens were taken from 77% of patients. Culture results showed that 29% (n = 65) of the patients had clinically significant growth of organisms. Of the 65 patients with clinically significant culture results, 49% (n = 32) were on an inappropriate empirical regimen. In 55%, the medication was not changed to a more appropriate antibiotic. In 72% of the patients with a negative culture, the culture report had no obvious effect on the duration or type of antibiotic being administered. Intravenous antibiotics were used in 60% of patients.
CONCLUSION: This study demonstrates a significant overuse of antibiotics, especially intravenous forms, despite a paucity of positive sepsis parameters and chest X-ray findings in these patients The duration of treatment could be shortened and an early switch policy introduced if culture results and sepsis profiles were taken into consideration, as there was a large number of unproven infections. Suggestions are made about how these improvements in prescribing could be made within the current administrative set-up of AMAUs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12848753     DOI: 10.1046/j.1469-0691.2003.00577.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  6 in total

1.  Antibiotic misuse: a prospective clinical audit in a French university hospital.

Authors:  C Pulcini; E Cua; F Lieutier; L Landraud; P Dellamonica; P M Roger
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-04       Impact factor: 3.267

2.  Adherence to Hospital Antibiotic Policy for Treatment of Escherichia coli ESBL in Urine.

Authors:  R Someshwaran; K Gnana Prakash; Shreeram A Deshpande; Anbu N Aravazhi
Journal:  J Clin Diagn Res       Date:  2016-03-01

3.  Different patterns of inappropriate antimicrobial use in surgical and medical units at a tertiary care hospital in Switzerland: a prevalence survey.

Authors:  Alexia Cusini; Silvana K Rampini; Vineeta Bansal; Bruno Ledergerber; Stefan P Kuster; Christian Ruef; Rainer Weber
Journal:  PLoS One       Date:  2010-11-16       Impact factor: 3.240

4.  Empirical use of antibiotics and adjustment of empirical antibiotic therapies in a university hospital: a prospective observational study.

Authors:  Julian Mettler; Mathew Simcock; Pedram Sendi; Andreas F Widmer; Roland Bingisser; Manuel Battegay; Ursula Fluckiger; Stefano Bassetti
Journal:  BMC Infect Dis       Date:  2007-03-26       Impact factor: 3.090

5.  Third generation cephalosporin use in a tertiary hospital in Port of Spain, Trinidad: need for an antibiotic policy.

Authors:  Lexley M Pinto Pereira; Marjorie Phillips; Hema Ramlal; Karen Teemul; P Prabhakar
Journal:  BMC Infect Dis       Date:  2004-12-15       Impact factor: 3.090

6.  Effectiveness of sequential intravenous-to-oral antibiotic switch therapy in hospitalized patients with gram-positive infection: the SEQUENCE cohort study.

Authors:  D Rodriguez-Pardo; C Pigrau; D Campany; V Diaz-Brito; L Morata; I C de Diego; L Sorlí; S Iftimie; R Pérez-Vidal; G García-Pardo; T Larrainzar-Coghen; B Almirante
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-05-14       Impact factor: 3.267

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.